Article
Immunology
Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin
Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Makoto Murata, Takanori Teshima
Summary: This article discusses the potential of MSC therapy in the treatment of acute GVHD, along with a comparison of studies on the two products, Remestemcel-L and Temcell. While Temcell's real-world efficacy was found to be equivalent to that observed in a prospective study, the precise position of Remestemcel-L/Temcell therapy in the treatment of acute GVHD remains to be determined.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Review
Cell & Tissue Engineering
Teng Li, Chengxin Luo, Jiasi Zhang, Ling Wei, Wei Sun, Qin Xie, Yan Liu, Yongli Zhao, Shuangnian Xu, Lihua Wang
Summary: The co-infusion of mesenchymal stem cells (MSCs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown improvement in engraftment and reduced risk of chronic graft-versus-host disease (cGVHD). However, the effects varied among different age and disease groups, suggesting potential benefits for certain populations.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Immunology
Sophie Servais, Frederic Baron, Chantal Lechanteur, Laurence Seidel, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, Johan Maertens, Xavier Poire, Wilfried Schroyens, Carlos Graux, Ann De Becker, Pierre Zachee, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin
Summary: BM-derived MSC from a third-party donor appeared to improve hematological function after alloHCT, but comparative studies are needed to confirm these results.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell & Tissue Engineering
Rashin Mohseni, Pouya Mahdavi Sharif, Maryam Behfar, Mohammad Reza Modaresi, Rohola Shirzadi, Mahta Mardani, Leila Jafari, Fahimeh Jafari, Zeynab Nikfetrat, Amir Ali Hamidieh
Summary: This study aimed to assess the safety and effectiveness of adipose tissue-derived mesenchymal stem cells (AT-MSCs) for pediatric patients with bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that a single injection of AT-MSCs partially improved the symptoms of patients and the treatment was safe and tolerable.
STEM CELL RESEARCH & THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Riccardo Masetti, Daniele Zama, Davide Leardini, Edoardo Muratore, Silvia Turroni, Patrizia Brigidi, Andrea Pession
Summary: The gut microbiome plays a significant role in hematopoietic stem cell transplantation, with its metabolites mediating interactions between intestinal microbial communities and the host. New data offer a fresh perspective on the role of microbiome-derived metabolites in transplant settings.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Yosuke Okada, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Aki Tanihara, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Shun-Ichi Kimura, Shinichi Kako, Noriko Oyama-Manabe, Yoshinobu Kanda
Summary: Pancreatic atrophy is associated with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. The recovery of pancreatic thickness plays a crucial role in body weight recovery, but pancreatic atrophy may have a negative impact on prognosis.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Hematology
Muzaffer Keklik, Burak Deveci, Serhat Celik, Kemal Deniz, Zeynep Burcin Gonen, Gokmen Zararsiz, Rabin Saba, Gulsah Akyol, Yusuf Ozkul, Leylagul Kaynar, Ertugrul Keklik, Ali Unal, Mustafa Cetin, Olcay Y. Jones
Summary: The safety and efficacy of mesenchymal stromal cell (MSC) therapy for steroid-refractory late acute graft versus host disease (late aGvHD) was evaluated and compared to acute GvHD (aGvHD) in a multicenter study. It was found that patients with late aGvHD had a higher response rate, lower non-relapse mortality (NRM), and improved survival probability at the 2-year follow-up, indicating the benefits of MSC treatment for late aGvHD.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani
Summary: Among 307 patients with SR-aGVHD, approximately 1/5 of patients showed resistance or intolerance to Ruxolitinib. The overall response rate to additional therapy was 36% in resistant patients with a median survival of 21 days; while 50% of intolerant patients continued to improve with additional therapy, with a median survival of 50 days. These data provide a baseline for future studies on SR-aGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
Summary: In this study, the clinical response to ruxolitinib in patients with steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation was investigated, and its safety profile was evaluated during the treatment course. The majority of patients treated with ruxolitinib showed significant treatment responses with a relatively well-tolerated safety profile, with lung involvement and matched related donors being associated with less favorable treatment response.
Article
Immunology
Yan Jiang, Jie Zhao, Minghui Wang, Fang Huang, Jiaqi Li, Rui Liu, Jiangbo Wan, Siguo Hao
Summary: This study demonstrates that MEXs exert their effects by inhibiting the immunomodulatory function of DCs, macrophages, and T lymphocytes, aiding in alleviating GVHD symptoms and preserving the antitumor effects of CD8+ T lymphocytes.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Hideaki Fujiwara
Summary: This article discusses the impact of allo-HSCT on intestinal microbiota and metabolites, as well as the mechanisms for regulating experimental GVHD through dietary intervention or metabolites produced by intestinal bacteria post-allo-HSCT. It also summarizes the major findings of microbiome-based immunotherapeutic approaches for tissue protection against experimental GVHD. Understanding the complex relationships within the gut microbiota-metabolites-host tissues axis is crucial for insight into GVHD pathogenesis and the development of new therapeutic strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Medicinal
Cong Wei, Xiaoting Zhang, Dan Liang, Jilong Yang, Jingwen Du, Chunyan Yue, Lan Deng
Summary: Ruxolitinib has been shown to be a safe and effective treatment for steroid-refractory GVHD in a Chinese population, with high overall response rates in acute GVHD patients and comparable overall survival rates between responders and non-responders in chronic GVHD patients. Common adverse events include cytopenia, cytomegalovirus reactivation, and infections, particularly in patients with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Immunology
Xiaomin Yang, Chengjuan Luo, Juan Qian, Xiaohang Huang, Jian Zhang, Jianmin Wang, Changying Luo, Xia Qin, Benshang Li, Jing Chen
Summary: Unedited HLA-matched allogeneic CAR-T cell therapy is an innovative, effective, and safe treatment for children with refractory/relapsed Burkitt lymphoma without obvious acute graft-versus-host disease (GVHD). Conditioning-free allogeneic hematopoietic stem cell transplantation (HSCT) from the same donor is feasible for a patient with full donor T-cell chimerism after allogeneic CAR-T. However, close monitoring for chronic GVHD is necessary post HSCT.
FRONTIERS IN IMMUNOLOGY
(2023)